Clinical Trial Update: A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing RPH-002 with Erbitux in unresectable metastatic or recurrent head and neck squamous cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• ERBITUX (cetuximab)
• RPH-002

Snippet

Sponsor: R-Pharm | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 3 | Status: COMPLETED